RxDoctor Payments Data

Ronica McBrayer, MD

Obstetrics · Midland, TXNPI 1215197496

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.4% of the total across 121 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AbbVie at 30.6% of the total.

$2,153in general payments, 2019–2025

Across 121 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$658
  • Astellas Pharma US Inc$167
  • Biogen$165
  • Bayer$162
  • Amgen$130
  • Axonics, Inc.$124
  • plus $748 from 21 others

What the payments were for

  • Food & beverage$2,14199%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,153 in reported general payments places this provider in the 65th percentile of 85 obstetrics providers in Texas.

See all obstetrics providers in Texas

Medicare billing

Part B allowed, 2024
$79,269
Medicare patients
119
Services billed
3,094

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide11$9,221
Estradiol45$2,609
SynthroidLevothyroxine Sodium25$1,209
Estradiol (Twice Weekly)Estradiol11$858
Levothyroxine Sodium73$444
Metformin Hcl ErMetformin Hcl39$197
Simvastatin13$184
Escitalopram Oxalate18$152
Citalopram HbrCitalopram Hydrobromide15$132
Rosuvastatin Calcium34$129
Fluconazole11$62
Zolpidem Tartrate11$41
Amlodipine Besylate11$20

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$30$9,22111 claims
AbbVieSynthroid$658$1,20925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 85 obstetrics providers in Texas.

Other obstetrics in Midland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →